Immunotherapy for older patients with cancer

被引：4

作者：

Araujo Vargas, Tatianny P. ^{[1
]}

Al-Humiqani, Abdullah ^{[1
,2
]}

Mata, Danilo Giffoni De Mello Morais ^{[1
,2
]}

Menjak, Ines B. ^{[1
,2
,3
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[2] Univ Toronto, Div Med Oncol & Hematol, Dept Med, Toronto, ON, Canada

[3] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr T2, Toronto, ON M4N3M5, Canada

来源：

CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE | 2023年 / 17卷 / 01期

关键词：

cancer; geriatric oncology; immunotherapy; CELL LUNG-CANCER; IMMUNE CHECKPOINT INHIBITORS; ELDERLY-PATIENTS; OPEN-LABEL; NIVOLUMAB; DOCETAXEL; PEMBROLIZUMAB; IPILIMUMAB; ADULTS; CHEMOTHERAPY;

D O I：

10.1097/SPC.0000000000000637

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Purpose of the reviewThe aim of this review is to describe the clinical use and tolerability of immune checkpoint inhibitors in older adults with solid tumors, where there is an abundance of evidence with recent updates including subgroups of older patients. Recent findingsStudies with updated analyses and subgroups of older patients show that in general older patients benefit as well as younger patients and tolerate immunotherapy very well. However, in some instances of combination therapies which may expose patients to more toxicity, the benefits are reduced, and careful selection of older patients, including adjunctive assessments such as geriatric assessment, can help to identify the appropriate treatment for an individual patient. Older adults remain underrepresented in clinical trials, including those involving immunotherapy. Therefore, efforts must be made to include more older patients in trials and to assess real-world evidence to inform decision-making.

引用

页码：37 / 46

页数：10

共 75 条

[1]

Akinboro O, 2022, J CLIN ONCOL, V40

[2] Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis. [J].

Akinboro, Oladimeji ;

Vallejo, Jonathon Joseph ;

Mishra-Kalyani, Pallavi Shruti ;

Larkins, Erin A. ;

Drezner, Nicole Lauren ;

Tang, Shenghui ;

Pazdur, Richard ;

Beaver, Julia A. ;

Singh, Harpreet .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[3] New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016 [J].

Berk-Krauss, Juliana ;

Stein, Jennifer A. ;

Weber, Jeffrey ;

Polsky, David ;

Geller, Alan C. .

AMERICAN JOURNAL OF PUBLIC HEALTH, 2020, 110 (05) :731-733

[4] Management of immunotherapy toxicities in older adults [J].

Bhandari, Shruti ;

Gill, Amitoj S. ;

Perez, Cesar A. ;

Jain, Dharamvir .

SEMINARS IN ONCOLOGY, 2018, 45 (04) :226-231

[5] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[6]

Borghaei H, 2021, J CLIN ONCOL, V39, P723, DOI 10.1200/JCO.20.01605

[7] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[8] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

[9] The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis [J].

Ciccarese, Chiara ;

Iacovelli, Roberto ;

Bria, Emilio ;

Palazzo, Antonella ;

Maiorano, Brigida Anna ;

Mosillo, Claudia ;

Carbone, Carmine ;

Piro, Geny ;

Tortora, Giampaolo .

JOURNAL OF IMMUNOTHERAPY, 2020, 43 (03) :95-103

[10] Immune checkpoint inhibitors and elderly people: A review [J].

Daste, Amaury ;

Domblides, Charlotte ;

Gross-goupil, Marine ;

Chakiba, Camille ;

Quivy, Amandine ;

Cochin, Valerie ;

de Mones, Erwan ;

Larmonier, Nicolas ;

Soubeyran, Pierre ;

Ravaud, Alain .

EUROPEAN JOURNAL OF CANCER, 2017, 82 :155-166

← 1 2 3 4 5 6 7 8 →